The Effect of Timing of Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

Neurosurgery

Volumn 77, Issue 2, 2015, Pages 248-253

  Han, Seunggu J ^a   Rutledge, W Caleb ^a   Molinaro, Annette M ^a,b   Chang, Susan M ^a   Clarke, Jennifer L ^a   Prados, Michael D ^a   Taylor, Jennie W ^a   Berger, Mitchel S ^a   Butowski, Nicholas A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Concurrent chemoradiation; Delay; Glioblastoma; Radiation; Temozolomide; Timing

Indexed keywords

BEVACIZUMAB; ENZASTAURIN; ERLOTINIB; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; ADJUVANT CHEMORADIOTHERAPY; AGED; ALGORITHM; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; NEUROSURGERY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937430802     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000766     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10): 987-996.
2. Froud PJ, Mates D, Jackson JS, et al. Effect of time interval between breastconserving surgery and radiation therapy on ipsilateral breast recurrence. Int J Radiat Oncol Biol Phys. 2000;46(2):363-372.
3. Vujovic O, Perera F, Dar AR, et al. Does delay in breast irradiation following conservative breast surgery in node-negative breast cancer patients have an impact on risk of recurrence? Int J Radiat Oncol Biol Phys. 1998;40(4):869-874.
4. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for nonsmall cell lung cancer: present status. Lung Cancer. 2001;31(1):43-56.
5. Ampil FL, Buechter KJ, Bairnsfather LE, Shockley WW. Timing and dosage of postoperative radiotherapy for squamous cell carcinoma of the upper aerodigestive tract. J Oral Maxillofac Surg. 1993;51(11):1194-1197.
6. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R. Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2001;49 (1):139-146.
7. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol. 2000;57(2):131-136.
8. Irwin C, Hunn M, Purdie G, Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol. 2007;85(3):339-343.
9. Lai R, Hershman DL, Doan T, Neugut AI. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2010;12(2):190-198.
10. Noel G, Huchet A, Feuvret L, et al. Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol. 2012;109(1):167-175.
11. Blumenthal DT, Won M, Mehta MP, et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol. 2009; 27(5):733-739.
12. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579-584.
13. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010; 12(6):608-613.
14. Butowski N, Chang SM, Lamborn KR, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011;13(12):1331-1338.
15. Clarke JL, Molinaro AM, Phillips JJ, et al. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014;16(7):984-990.
16. Molinaro AM, Lostritto K, van der Laan M. partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction. Bioinformatics. 2010;26(10):1357-1363.
17. Lostritto K, Strawderman RL,Molinaro AM. A partitioning deletion/substitution/addition algorithm for creating survival risk groups. Biometrics. 2012;68(4): 1146-1156.
18. Iuchi THK, Hatano K, Kodama T, et al. Brain deformation after surgery of glioblastoma should we take MRI for planning of irradiation? Poster presented at: ESTRO 29 (meeting of European Society for Radiotherapy and Oncology); September 12-16, 2010; Barcelona, Spain.
19. Peker S, Abacioglu U, Sun I, Yuksel M, Pamir MN. Irradiation after surgically induced brain injury in the rat: timing in relation to severity of radiation damage. J Neurooncol. 2004;70(1):17-21.
20. Barazzuol L, Burnet NG, Jena R, Jones B, Jefferies SJ, Kirkby NF. A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. J Theor Biol. 2010;262(3):553-565.
21. Chinot OL, Barrié M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25(12):1470-1475.